期刊文献+

人附睾分泌蛋白4联合CA125在卵巢恶性肿瘤与子宫内膜异位症鉴别诊断中的价值 被引量:55

Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors
原文传递
导出
摘要 目的探讨血清人附睾分泌蛋白4(HE4)联合CA125水平检测在卵巢恶性肿瘤与子宫内膜异位症鉴别诊断中的价值。方法采用酶联免疫吸附试验(ELISA)检测卵巢子宫内膜异位囊肿(内异症组)46例、卵巢上皮性癌(卵巢癌组)36例、卵巢非内膜异位良性肿瘤(良性肿瘤组)60例和健康妇女(对照组)50例血清中HFA和CA125水平,结果以中位数表示。血清HE4和CA125正常值分别为0~150pmo/L和0~35kU/L,单独或联合检测时,其中任一指标高于正常上限即定为阳性。通过制作受试者工作特征(ROC)曲线,以曲线下面积(AUC)反映诊断的准确性;以Mann.Whitney U检验及相关性分析探讨两项指标单独或联合检测用于诊断卵巢内异症囊肿的价值。结果(1)HFA水平:内异症、对照、良性肿瘤组妇女血清HE4水平分别为52.4、51.0、50.0pmol/L,3组比较,差异无统计学意义(P〉0.05),卵巢癌组患者HE4水平为507.5pmol/L,与其他3组分别比较,差异均有统计学意义(P〈0.05)。(2)CA125水平:卵巢癌、内异症、良性肿瘤及对照组妇女血清CA125水平分别为743.0、84.9、15.4、11.5kU/L,卵巢癌组与其他3组比较,差异均有统计学意义(P〈0.05)。(3)单项检测结果:卵巢癌组以内异症组为参照时,HFA和CA125单项检测的AUC分别0.933和0.821,其特异度为95%时的敏感度分别为79.6%和49.0%;内异症组以对照组为参照时的AUC为0.453;以良性肿瘤组为参照时的AUC为0.496。(4)联合检测结果:卵巢癌组以内异症组为参照时,HFA联合CA125检测的AUC为0.936,其特异度为95%时的敏感度为81.0%。结论HE4水平可作为卵巢内异症囊肿的鉴别诊断依据之一,HFA联合CA125水平检测能有效鉴别卵巢内异症囊肿和卵巢恶性肿瘤。 Objective To investigate the value of human epididymis secretory protein 4 (HFA) combined with CAI25 assay in differential diagnosis of endometriosis cyst and ovarian malignant tumor. Methods The level of HE4 and CAt2s were measured by enzyme-linked immunosorbent assay (ELISA) in the serum specimens of 46 cases in endometriosis cyst group, 36 cases in malignant ovarian tumor group,60 cases in benign ovarian diseases and 50 women in healthy women group. Those results were shown with median level. The normal range were 0 -150 pmol/L in HE4 and 0 -35 kU/L, which either one was more than the threshold value defined as positive index. The sensitivity of assay was evaluated by receiver operating characteristic (ROC) curve, the relation and value of HF4 or CA125 alone and combination assay in diagnosis of endometriosis was analyzed by Mann-Whitney U test and correlation analysis. Results ( 1 ) HE4: the median levels of HE4 were 52.4, 51.0, 50. 0 pmol/L in group of endometriosis, normal control and benign ovarian tumor, which didn't show statistical difference. However, HE4 was 507. 5 pmol/L in ovarian cancer group, which was significantly higher than those of 3 groups ( P 〈 0. 05 ). ( 2 ) CA125 : there were significant different in median level of CA12s was observed as 743. 0 kU/L in ovarian cancer, 84. 9 kU/L in endoemtriosis, 15.4 kU/L in benign ovarian disease, and 11.5 kU/L in healthy women ( P 〈 0.05). (3) The single assay: when compared with that in endometriosis group, receiver operating characteristic area under the curve(ROC-AUC) were 0. 933 in HE4 alone and 0. 821 in CA125 alone assay in ovarian cancer group. The specificity was 95% and the sensitivity was 79.6% and 49.0%. (4) The combination assay: when compared with those in endometriosis group, the ROC-AUC was 0. 936, the specificity was 95% and the sensitivity was 81.0% in ovarian cancer. Conclusions Measurement of HE4 could be used in differential diagnosis of endometriosis cyst. And the combination of HE4 and CA125 assay could discriminate ovarian endometriosis cysts from ovarian malignant tumors effectively.
出处 《中华妇产科杂志》 CAS CSCD 北大核心 2010年第5期363-366,共4页 Chinese Journal of Obstetrics and Gynecology
关键词 卵巢肿瘤 子宫内膜异位症 附睾分泌蛋白质类 CA-125抗原 肿瘤标记 生物学 Ovarian neoplasms Endometriosis Epididymal secretory proteins CA-125 antigen Tumor markers, biological
  • 相关文献

参考文献7

  • 1Giudice LC,Kao LC.Endometriosis.Lancet,2004,364:1789-1799.
  • 2Moore RG,Brown AK,Miller MC,et al.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.Cynecol Oncol,2008,108:402-408.
  • 3Havrilesky LJ,Whitehead CM,Rubatt JM,et al.Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.Gynecol Oncol,2008,110:374-382.
  • 4Drapkin R,von Horsten HH,Lin Y,et al.Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.Cancer Res,2005,65:2162-2169.
  • 5Galgano MT,Hampton GM,Frierson HF Jr.Comprehensive analysis of HE4 expression in normal and malignant human tissues.Mod Pathol,2006,19:847-853.
  • 6Moore RG,Brown AK,Miller MC,et al.Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.Gynecol Oncol,2008,110:196-201.
  • 7Cagnon A,Ye B.Discovery and application of protein biomarkers for ovarian cancer.Curr Opin Obstet Gynecol,2008,20:9-13.

同被引文献427

引证文献55

二级引证文献280

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部